… because these studies did not focus on patients with venous thromboembolism (18-22), …
patients with venous thromboembolism who received at least 3 months of oral anticoagulant …

Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer.
These patients are at an increased risk of developing VTE and are more likely to have a …

… 9 ; (2) patients were to receive oral anticoagulant therapy with an … anticoagulation; and (3)
recurrent VTE (as defined by the study authors) was reported during extended anticoagulation…

… new oral anticoagulants (NOACs), which can be given in fixed doses and produce such a
predictable anticoagulant … all-oral regimens, which can replace parenteral anticoagulants and …

… We will present the case that the new oral anticoagulants provide major advantages to
warfarin that should make them first-line agents to prevent thromboembolism in patients with AF …

… We systematically reviewed and meta-analysed clinical outcomes with direct oral anticoagulants
(DOAC: dabigatran, rivaroxaban, apixaban or edoxaban) for treatment of acute VTE. …

… In patients with VTE and cancer, oral anticoagulation poses a higher risk of bleeding, and
such patients are more prone to recurrences. Alternative treatment with LMWH could be safer …

… Studies that focus on patients with temporary risk factors (such as surgery, pregnancy, or …
periods of oral anticoagulant therapy are sufficient to prevent recurrent thromboembolic disease…

… , we compared six months of oral anticoagulant therapy with anticoagulant therapy continued
indefinitely in patients who had had a second episode of venous thromboembolism. Of 227 …

… In current treatment guidelines, patients with ‘non valvular’ AF and a CHA2DS2-VASc … oral
anticoagulation, whether with a vitamin K antagonist (VKA) or a non-VKA oral anticoagulant (…